2022-08-20 高雄萬豪酒店 10F皇喜會議室 10D-1
時間主題講者座長摘要簡報
14:10 ~ 14:20
PD04-1: Active surveillance in Taiwanese men with localized prostate cancer: Outcomes and predicting models
查舫宇
楊啟瑞,
王賢祥
14:20 ~ 14:30
PD04-2: Overall survival with Darolutamide versus placebo in combination with androgen-deprivation therapy and Docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial
馮思中
楊啟瑞,
王賢祥
14:30 ~ 14:40
PD04-3: The role of urine metabolomics in predicting clinically significant prostate cancer
陳忠信
楊啟瑞,
王賢祥
14:40 ~ 14:50
PD04-4: Comparison of the clinical outcomes of chemotherapy and novel hormone agents in pre-chemotherapy and post-chemotherapy settings for treatment of metastatic castration-resistant prostate cancer
吳芃諺
楊啟瑞,
王賢祥
14:50 ~ 15:00
PD04-5: Prostate health index density outperforms prostate health index in clinically significant prostate cancer detection
蔣智宏
楊啟瑞,
王賢祥
15:00 ~ 15:10
PD04-6: 4-year experience in cmuh for learning curve of MRI/Ultrasound fusion-guided prostate biopsy
李柏毅
楊啟瑞,
王賢祥